India, Oct. 20 -- Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a financial update reflecting a 19% increase in group revenue and key operational highlights for the third quarter ended September 30, 2026. The company also reaffirmed its full-year 2026 revenue guidance.
Company ProfileTelix Pharmaceuticals develops targeted theranostics aimed at improving outcomes for cancer patients. The company's commercial portfolio is led by precision imaging products, including Illuccix and Gozellix, both gallium-68 PSMA PET imaging agents for prostate cancer, as well as Pixclara, an FDA-approved imaging agent for evaluating gliomas.
Building on its diagnostics franchise, Telix is also advancing a late-stage therapeutic pipeli...